Literature DB >> 12640307

Erosive enterocolitis in mycophenolate mofetil-treated renal-transplant recipients with persistent afebrile diarrhea.

Bart D Maes1, Ignace Dalle, Karen Geboes, Michael Oellerich, Victor W Armstrong, Pieter Evenepoel, Benny Geypens, Dirk Kuypers, Maria Shipkova, Karel Geboes, Yves F Ch Vanrenterghem.   

Abstract

BACKGROUND: Diarrhea is the most frequently reported adverse event in mycophenolate mofetil (MMF)-treated transplant patients. The aim of this study was to explore the gastrointestinal tract in MMF-treated renal transplant recipients with persistent afebrile diarrhea to characterize its nature and etiology.
METHODS: Renal transplant recipients with persistent afebrile diarrhea (daily fecal output >200 g) were prospectively investigated for infections, morphologic, and functional (gastrointestinal motility and intestinal absorptive capacity) integrity of the gastrointestinal tract; 26 patients met the inclusion criteria.
RESULTS: All but one patient had an erosive enterocolitis. Seventy percent of the patients had malabsorption of nutrients, contributing to the diarrhea. In +/-60%, an infectious origin was demonstrated and successfully treated with antimicrobial agents without changes in immunosuppressive regimen. In +/-40%, no infection occurred, but a Crohn's disease-like pattern of inflammation was noted. These patients also had a less pronounced bile-acid malabsorption but a significant faster colonic transit time, correlating with the trough level of mycophenolic acid (MPA). Cessation of MMF, however, was associated with allograft rejection in one third of these patients.
CONCLUSIONS: Persistent afebrile diarrhea in renal transplant recipients is characterized by erosive enterocolitis, which is of infectious origin in +/-60%. In +/-40%, a Crohn's disease-like (entero-)colitis was present. Because reduction or cessation of MMF was the only effective therapy, MPA or one of its metabolites may be suggested as a possible cause. However, reduction or cessation of MMF was associated with an increased risk for rejection.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12640307     DOI: 10.1097/01.TP.0000053753.43268.F0

Source DB:  PubMed          Journal:  Transplantation        ISSN: 0041-1337            Impact factor:   4.939


  23 in total

Review 1.  Crohn's disease and infections: a complex relationship.

Authors:  Gert De Hertogh; Karel Geboes
Journal:  MedGenMed       Date:  2004-08-10

Review 2.  Clinical pharmacokinetics and pharmacodynamics of mycophenolate in solid organ transplant recipients.

Authors:  Christine E Staatz; Susan E Tett
Journal:  Clin Pharmacokinet       Date:  2007       Impact factor: 6.447

3.  The occurrence of diarrhea not related to the pharmacokinetics of MPA and its metabolites in liver transplant patients.

Authors:  Zhang Wei Xia; Chen Yong Jun; Chen Hao; Chen Bing; Shi Min Min; Xie Jun Jie
Journal:  Eur J Clin Pharmacol       Date:  2010-05-15       Impact factor: 2.953

Review 4.  The influence of pharmacogenetics and cofactors on clinical outcomes in kidney transplantation.

Authors:  Nicolas Picard; Pierre Marquet
Journal:  Expert Opin Drug Metab Toxicol       Date:  2011-03-25       Impact factor: 4.481

5.  A case of new onset Crohn's disease after renal transplantation.

Authors:  Ian J Stewart; Joseph P Gallagher; William J Dahms
Journal:  Gastroenterol Hepatol (N Y)       Date:  2008-12

6.  Giardia lamblia infection after pancreas-kidney transplantation.

Authors:  Ann Abkjaer Kristensen; Rune Horneland; Henrik Birn; My Svensson
Journal:  BMJ Case Rep       Date:  2016-01-18

Review 7.  Enteric-coated mycophenolate sodium: tolerability profile compared with mycophenolate mofetil.

Authors:  Matthias Behrend; Felix Braun
Journal:  Drugs       Date:  2005       Impact factor: 9.546

8.  Risk of diarrhoea in a long-term cohort of renal transplant patients given mycophenolate mofetil: the significant role of the UGT1A8 2 variant allele.

Authors:  Jean-Baptiste Woillard; Jean-Philippe Rerolle; Nicolas Picard; Annick Rousseau; Mireille Drouet; Eliza Munteanu; Marie Essig; Pierre Marquet; Yann Le Meur
Journal:  Br J Clin Pharmacol       Date:  2010-06       Impact factor: 4.335

9.  Debilitating diarrhoea and weight loss due to colitis in two RA patients treated with leflunomide.

Authors:  P Verschueren; A K Vandooren; R Westhovens
Journal:  Clin Rheumatol       Date:  2004-11-23       Impact factor: 2.980

10.  Steatorrhoea complicating post-infectious diarrhoea in a renal transplant patient on mycophenolate mofetil therapy.

Authors:  Senyo Tagboto; Farman Akhtar
Journal:  Clin Exp Nephrol       Date:  2008-12-10       Impact factor: 2.801

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.